Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
Follow ALLO
Allogene Therapeutics, Inc. (ALLO) Altman Z-score
Allogene Therapeutics, Inc.'s Altman Z-score for fiscal 2024 is −3.73, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | −3.73 | (1.75) |
| FY2023 | −1.98 | (2.72) |
| FY2022 | 0.73 | (7.78) |
| FY2021 | 8.51 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.49 | — | 0.59 | |
| Retained earnings / total assets | (3.32) | — | −4.64 | |
| EBIT / total assets | (0.50) | — | −1.64 | |
| Market value of equity / total liabilities | 3.28 | — | 1.97 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −3.73 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −7.45 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| OCS Oculis Holding AG compare | 10.5× |
| NGNE Neurogene Inc. compare | 8.7× |
| ALT Altimmune, Inc. compare | 0.2× |
| CBIO Crescent Biopharma, Inc. compare | −0.1× |
| ARVN Arvinas, Inc. compare | −0.6× |
| RGNX REGENXBIO Inc. compare | −2.6× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | −3.2× |
| ALLO Allogene Therapeutics, Inc. | −3.7× |
| YDES YD Bio Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets